– USA, NJ – Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today the appointment of Eric J. Ende, M.B.A, M.D., to its Board of Directors, effective Monday, April 3, 2017.
Dr. Ende is a life sciences executive with over 20 years of financial leadership experience. Dr. Ende currently serves as President of Ende BioMedical Consulting Group, which is focused on helping life sciences companies raise capital, identify licensing partners, and optimize corporate structure as well as analyzing both private and public investment opportunities for clients within the life sciences industry. He also currently serves on the Technology Transfer Committee of Mount Sinai Innovation Partners.
Roelof Rongen, Chief Executive Officer of Matinas stated, “We are thrilled to have Dr. Ende join the Matinas Board of Directors during such an important time in the Company’s evolution as we prepare to report clinical data in the near-term which we believe has the potential to validate our cochleate technology platform and prove to be transformative for Matinas. His broad experience and proven track record in propelling companies to their next phase of growth will be integral as we continue to advance our corporate and clinical strategies.”
Previously, Dr. Ende consulted with Icahn Enterprises in connection with their efforts to appoint board members at Forest Labs, Genzyme, Biogen IDEC, and Amylin. From 2010 to 2011, he served as a Director on Genzyme’s Board until it was acquired by Sanofi-Aventis in 2011 for $20 billion. During his tenure on Genzyme’s Board of Directors, Dr. Ende was a member of the Audit and Risk Management Committees. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. From 2000 to 2002, Dr. Ende served as the senior biotechnology analyst at Bank of America Securities and, from 1997 to 2000, he served as a biotechnology analyst at Lehman Brothers. Over the course of his career as a biotechnology analyst, Dr. Ende was named to Institutional Investor’s All-American Equity Research Team six times as well as to The Greenwich Survey list of top analysts.
“There is a great need for transformational technologies to address a number of unmet needs in a range of multi-drug resistant infections. Matinas’ cochleate platform delivery technology has showcased its broad utility and ability to provide targeted delivery and reduce toxicity. I am excited to be joining the Company at such an exciting time and look forward to working with the management team and board to leverage this proprietary technology to provide much needed solutions for physicians and patients and unlock tremendous shareholder value,” commented Dr. Ende.
Dr. Ende received his M.B.A. in Finance & Accounting from NYU – Stern Business School, an M.D. from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. The Company’s proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company’s lead drug candidate MAT2203 is an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent). MAT2203 is currently being studied in two separate Phase 2 studies with topline results of each trial expected to be announced in the second quarter of 2017. MAT2501, the Company’s orally-administered encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections, reported positive topline data from the Phase 1 single-ascending dose study in healthy volunteers. Matinas is advancing its MAT2501 Phase 1 program in preparation of a Phase 2 study in patients.
For more information : http://www.matinasbiopharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.